You are here: Industry Insights > Semaglutide

News List

Novo Nordisk plans study of oral semaglutide in obesity pharmatimes
April 23, 2021
Novo Nordisk is planning to initiate a Phase IIIa study of oral semaglutide in obesity, the Danish pharma company announced 21st.
FDA refuses Novo Nordisk’s once-weekly semaglutide pharmatimes
March 25, 2021
Novo Nordisk has received a refusal to file letter from the US Food and Drug Administration (FDA) for a label expansion application for semaglutide.
Gilead, Novo Nordisk expand NASH clinical collaboration expresspharma
March 19, 2021
Gilead Sciences and Novo Nordisk announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH).
Lilly’s tirzepatide claims head-to-head trial win against injectable semaglutide pharmatimes
March 05, 2021
Eli Lilly’s investigational treatment tirzepatide has demonstrated superior A1C and body weight reduction compared to injectable semaglutide in adults with type 2 diabetes.
Novo Nordisk invests in facility expansion at production site in Denmark pharmatimes
February 26, 2021
Novo Nordisk will invest DKK 500 million (£57.96m) to expand facilities at an existing production site in Måløv, Denmark.
Novo Nordisk’s semaglutide cuts body weight in large-scale trial pharmatimes
February 24, 2021
Novo Nordisk’s glucagon-like peptide-1 (GLP-1) agonist semaglutide significantly cut body weight in a large-scale trial of adults who are overweight or obese.
UK researchers find semaglutide could be a ‘game changer’ drug to fight obesity expresspharma
February 18, 2021
The drug, semaglutide, works by hijacking the body's own appetite-regulating system in the brain leading to reduced hunger and calorie intake, according to the study.
Novo Nordisk eyes EU approval for once-weekly semaglutide pharmatimes
December 21, 2020
Danish pharma company Novo Nordisk has submitted a marketing authorisation application the European Medicines Agency (EMA), seeking approval for once-weekly semaglutide for weight management.
Gilead and Novo Nordisk’s NASH trial meets primary endpoint pharmatimes
November 18, 2020
Gilead and Novo Nordisk have announced that a phase II proof-of-concept trial evaluating combination treatments for non-alcoholic steatohepatitis (NASH) met its primary endpoint.
Novo Nordisk's AM833 shows early success in obesity trials pharmatimes
June 22, 2020
Novo Nordisk has unveiled headline results from two clinical trials with a novel once-weekly subcutaneous amylin analogue (AM833) - a Phase II monotherapy trial and a Phase I combination trial of AM833 and once-weekly subcutaneous semaglutide.

Previous page 1 2 3 4 Next page